Half the funding is a Chief Scientist grant.
Meytag Technology Incubator portfolio company Biocep Ltd. has raised NIS 2 million. Half the financing is a convertible loan from current shareholders and a group investors, including Meytag director Dr. Shmuel Cabilly, a pioneer in genetic engineering. The other half is a grant from the Office of the Chief Scientist.
Biocep is developing an improved method of separation of immuno-magnetic marked cells. The patented Cell Enrichment Process (CEP) has three main uses: separation of fetal stem cells from the mother's blood in order to diagnose congenital defects in the early stages of pregnancy; separation of peripheral stem sells for implants and the strengthening of the immune system in cancer patents undergoing chemotherapy; and the separation of tumor cells from the bloodstream for improved cancer disease management.
Published by Globes [online], Israel business news - www.globes-online.com - on July 22, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010